Table 3 |
||||||
|
Tumor Rapamycin Levels |
||||||
|
24 hours |
48 hours |
|||||
|
|
||||||
|
Treatment Groups |
Rapamycin Level (ng/ml) |
p value* |
Number of Mice |
Rapamycin Level (ng/ml) |
p value** |
Number of Mice |
|
|
||||||
|
Treatment Trial (Tumor bearing) |
||||||
|
0.4% Direct Topical Rapamycin |
13.8 ± 0.7 |
0.12 |
3 |
14.2 ± 1.8 |
0.33 |
3 |
|
0.8% Indirect Topical Rapamycin |
34.2 ± 9.6 |
0.37 |
3 |
25.8 ± 7.8 |
0.65 |
3 |
|
0.8% Direct Topical Rapamycin |
59.6 ± 23.5 |
N/A |
3 |
21.0 ± 5.9 |
N/A |
3 |
|
0.16 mg Rapamycin IP |
421.8 ± 119.4 |
0.03 |
2 |
323.7 ± 98.1 |
0.03 |
2 |
|
|
||||||
|
* Compared to 0.8% direct treatment 24 hr tumor level. ** Compared to 0.8% direct treatment 48 hr tumor leve |
||||||
|
Rauktys et al. BMC Dermatology 2008 8:1 doi:10.1186/1471-5945-8-1 |
||||||
